• If you are wondering whether Insulet's current share price lines up with its underlying worth, or if the market is mispricing it, this article walks through that question step by step so you can form your own view.
• At a last close of US$238.82, Insulet's stock has seen a 1.7% decline over the past week, a 2.7% decline over the past month, and is down 15.6% year to date and 3.8% over the past year, with a 22.4% decline over three years and 8.1% decline over five years.
• These moves have put valuation back in focus for many investors looking at Insulet today, especially as the market reassesses expectations around the business and its sector. Recent commentary has centred on whether the current price reflects a fair balance between the company’s growth prospects and the risks investors are pricing in.
• On our framework of six valuation checks, Insulet scores 2 out of 6 for being undervalued. Next we will look at how different valuation approaches view that score, before finishing with a more complete way to think about what the stock might be worth.

Insulet scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Insulet Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash Insulet could generate in the future, then discounts those cash flows back into today’s dollars to arrive at an implied value per share.

For Insulet, the model starts with last twelve month Free Cash Flow of about US$375.9 million. Analysts and extrapolations then project Free Cash Flow out over the next decade, with the 2030 estimate at US$914.0 million based on a 2 Stage Free Cash Flow to Equity approach. Beyond the first few analyst covered years, Simply Wall St extends the projections using its own growth assumptions.

When all forecast cash flows from 2026 to 2035 are discounted back and combined, the DCF model points to an estimated intrinsic value of about US$295.58 per share. Compared with the recent share price of US$238.82, this implies the stock trades at around a 19.2% discount to that intrinsic value, which suggests the DCF view is that Insulet is undervalued on this metric.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Insulet is undervalued by 19.2%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Insulet Price vs Earnings

For a profitable company like Insulet, the P/E ratio is a useful way to relate what you are paying per share to the earnings the business is currently generating. It gives a quick sense of how much the market is willing to pay for each dollar of earnings.

What counts as a normal or fair P/E often reflects how the market views a company’s growth potential and risk. Higher growth or perceived resilience can justify a higher multiple, while more uncertainty or weaker profitability can point to a lower one.

Insulet currently trades on a P/E of 68.04x. That sits above the Medical Equipment industry average of 27.21x and the peer average of 38.28x. Simply Wall St’s Fair Ratio for Insulet is 32.64x, which is its proprietary estimate of an appropriate P/E given factors such as the company’s earnings growth, profit margin, industry, market cap and risk profile. Because this Fair Ratio is tailored to Insulet, it can be more informative than a simple comparison with broad industry or peer averages.

Compared with the Fair Ratio of 32.64x, Insulet’s current P/E of 68.04x screens as richer than what that framework suggests.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Insulet Narrative

Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St’s Community page you can use Narratives, where you set out your story for Insulet, link that story to specific forecasts for revenue, earnings and margins, and see the Fair Value that results compared with today’s price. The numbers update as new news or earnings arrive. For example, one investor might build a Narrative that fits the higher analyst price target of US$400.0, while another might lean toward the lower US$300.0 view. Both can clearly see how their different assumptions about Omnipod adoption, competition and margins translate into different Fair Values and clearer buy or sell decisions.

Do you think there's more to the story for Insulet? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.